BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26782438)

  • 1. miR-125a-5p expression is associated with the age of breast cancer patients.
    He H; Xu F; Huang W; Luo SY; Lin YT; Zhang GH; Du Q; Duan RH
    Genet Mol Res; 2015 Dec; 14(4):17927-33. PubMed ID: 26782438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic potential of TSTA3 in breast cancer and its regulation by the tumor suppressors miR-125a-5p and miR-125b.
    Sun Y; Liu X; Zhang Q; Mao X; Feng L; Su P; Chen H; Guo Y; Jin F
    Tumour Biol; 2016 Apr; 37(4):4963-72. PubMed ID: 26531722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance.
    Hashiguchi Y; Nishida N; Mimori K; Sudo T; Tanaka F; Shibata K; Ishii H; Mochizuki H; Hase K; Doki Y; Mori M
    Int J Oncol; 2012 May; 40(5):1477-82. PubMed ID: 22322911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-4728-3p could act as a marker of HER2 status.
    Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
    Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant expression of a five-microRNA signature in breast carcinoma as a promising biomarker for diagnosis.
    Bitaraf A; Babashah S; Garshasbi M
    J Clin Lab Anal; 2020 Feb; 34(2):e23063. PubMed ID: 31595567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab.
    Nishida N; Mimori K; Fabbri M; Yokobori T; Sudo T; Tanaka F; Shibata K; Ishii H; Doki Y; Mori M
    Clin Cancer Res; 2011 May; 17(9):2725-33. PubMed ID: 21220473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.
    Hsieh TH; Hsu CY; Tsai CF; Long CY; Chai CY; Hou MF; Lee JN; Wu DC; Wang SC; Tsai EM
    Oncotarget; 2015 Jan; 6(1):494-509. PubMed ID: 25504437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced miR-125a-5p expression is associated with gastric carcinogenesis through the targeting of E2F3.
    Xu Y; Huang Z; Liu Y
    Mol Med Rep; 2014 Nov; 10(5):2601-8. PubMed ID: 25231560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
    Yan LX; Huang XF; Shao Q; Huang MY; Deng L; Wu QL; Zeng YX; Shao JY
    RNA; 2008 Nov; 14(11):2348-60. PubMed ID: 18812439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lncRNA HOXA11-AS acts as a tumor promoter in breast cancer through regulation of the miR-125a-5p/TMPRSS4 axis.
    Xu Y; Ren Z; Wang X; Ren M
    J Gene Med; 2022 May; 24(5):e3413. PubMed ID: 35106863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
    Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
    Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
    Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1.
    Yan L; Yu MC; Gao GL; Liang HW; Zhou XY; Zhu ZT; Zhang CY; Wang YB; Chen X
    J Cell Biochem; 2018 Nov; 119(11):8773-8783. PubMed ID: 30076753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin exerts inhibitory effects on undifferentiated nasopharyngeal carcinoma by inhibiting the expression of miR-125a-5p.
    Gao W; Chan JY; Wong TS
    Clin Sci (Lond); 2014 Nov; 127(9):571-9. PubMed ID: 24896104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
    Wang B; Li J; Sun M; Sun L; Zhang X
    IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of MicroRNA-200 family in human breast cancer is associated with lymph node metastasis.
    Xu F; He H; Huang W; Lin Y; Luo S; Du Q; Duan R
    Clin Transl Oncol; 2016 Mar; 18(3):283-8. PubMed ID: 26201425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation Between miR-497-5p Expression With Clinicopathological Characteristics and Prognosis in Patients With Breast Cancer.
    Zhang Z; Zhou Y; Liang S
    Appl Immunohistochem Mol Morphol; 2024 Apr; 32(4):200-205. PubMed ID: 38497335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
    Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
    BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-Seq Identifies Circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as Potential Biomarkers for Acute Ischemic Stroke.
    Tiedt S; Prestel M; Malik R; Schieferdecker N; Duering M; Kautzky V; Stoycheva I; Böck J; Northoff BH; Klein M; Dorn F; Krohn K; Teupser D; Liesz A; Plesnila N; Holdt LM; Dichgans M
    Circ Res; 2017 Sep; 121(8):970-980. PubMed ID: 28724745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of microRNA-125a-5p upregulates the TAZ-EGFR signaling pathway and promotes retinoblastoma proliferation.
    Zhang Y; Xue C; Zhu X; Zhu X; Xian H; Huang Z
    Cell Signal; 2016 Aug; 28(8):850-60. PubMed ID: 27094723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.